



Date: February 20, 2024

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Introduction Report Pursuant to 18 V.S.A. § 4637(c)

To Whom It May Concern:

Today February 20, 2024, Catalyst Pharmaceuticals, Inc. in pursuant to 18 V.S.A. § 4637(b), is submitting a new drug introduction notice for the following (the "Product"):

NDC	Product Description	WAC
69616-0264-38	AGAMREE 40 mg/mL Bottle containing 100 mL	\$9,500

Catalyst Pharmaceuticals, Inc. now provides the following additional information pursuant to 18 V.S.A. § 4637(c).

- 1. US and international marketing and pricing plans used at launch:** Catalyst Pharmaceuticals, Inc. declines to provide this information in accordance with 18 V.S.A. § 4637(d).
- 2. Estimated volume of patients:** 18 patients a month
- 3. Whether the FDA granted breakthrough therapy designation or priority review:** No
- 4. Date and price of acquisition:** N/A

Catalyst Pharmaceuticals, Inc. provides this report consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions.

Thank you for your consideration.

Sincerely,

Kay Shafeek

Sr. Director, Revenue, Pricing & Govt Programs